FRONTEO : partners with Springer Nature to develop new services for interdisciplinary scientific paper analysis

　FRONTEO, Inc. (HQ: Minato-ku, Tokyo; CEO: Masahiro Morimoto) announces that it has partnered with Springer Nature (HQ: Berlin, Germany; CEO: Frank Vrancken Peeters) to develop new services by utilizing article information.

　Springer Nature is a global academic publishing company headquartered in Germany with offices globally. The company publishes many excellent academic journals and books, including Nature, the most representative scientific journal, and also provides databases and research services. In this partnership FRONTEO will develop a new biological science information analysis platform, by combining the strengths of Springer Nature's article data published in more than 600 influential journals and FRONTEO's natural language analysis AI technologies.

FRONTEO released Amanogawa in July 2020 as an AI system for researching and analyzing papers, and it is currently being deployed by universities, pharmaceutical companies, medical institutions, and other research organizations. The system uses as its data source information on articles in PubMed (https://pubmed.ncbi.nlm.nih.gov/), the biomedical article database operated by the National Center for Biomedical Information of the National Library of Medicine.

　On the other hand, since Springer Nature's article data are not only the abstracts but also the full text, it is anticipated that having AI learn from them will lead to more advanced analysis and information extraction. Furthermore, those articles cover a wide range of fields such as biomedicine, science, environment, materials science, psychology, engineering, nutrition, etc. By analyzing these data with AI, it is expected to enable comprehensive analysis including papers in various fields that have not been connected, and to lead to the sharing of knowledge across academic boundaries and the creation of new innovation.

Prathik Roy, Director, Data Solutions and Strategy, Springer Nature said:　
"Springer Nature has been in the forefront of leading research in the space of life sciences and pharma. We look forward to this new collaboration with FRONTEO to provide researchers and data scientists with great insight into research conducted in the life sciences which combines the power of Springer Nature's rich dataset and FRONTEO's state of the art AI solution."

　FRONTEO will continue to contribute to the development of innovative studies by providing solutions that utilize in-house developed AI, which has strengths in natural language processing.

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

■ About Amanogawa URL:　URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/
Amanogawa is an article-seeking AI system with FRONTEO's unique AI engines Concept Encoder (conceptencoder™). When a researcher enters a sentence such as a word or hypothesis of interest, Concept Encoder detects articles related to the input content in a moment from a large number of articles on PubMed. Search results are plotted in a map based on the degree of similarity between articles, and the relevance can be confirmed at a glance, and a visual article search that has not been done before can be performed by dragging the detected article information on the map to narrow down the search. In addition, search results are listed in descending order of relevance, and abstracts are listed, which greatly streamlines the search for papers. This will assist people in discovering events and new drug targets from difficult-to-notice perspectives. Patent No. 6976537

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder (trademark: conceptencoder, reading: concept encoder)", and "Looca Cross", which are specialized in natural language processing. It is a data analysis company that supports the business of companies by extracting meaningful and important information from a huge amount of text data. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, Amanogawa, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.